بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significant cause » significant change (توسيع البحث), significant changes (توسيع البحث), significant gap (توسيع البحث)
significant event » significant effect (توسيع البحث), significant level (توسيع البحث), significant effects (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significant cause » significant change (توسيع البحث), significant changes (توسيع البحث), significant gap (توسيع البحث)
significant event » significant effect (توسيع البحث), significant level (توسيع البحث), significant effects (توسيع البحث)
-
1
-
2
-
3
Adverse cardiovascular events by immune checkpoint inhibitor.
منشور في 2024الموضوعات: "…adverse cardiovascular events…"
-
4
-
5
Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events.
منشور في 2024الموضوعات: "…adverse cardiovascular events…"
-
6
Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE.
منشور في 2024الموضوعات: "…adverse cardiovascular events…"
-
7
-
8
-
9
-
10
-
11
-
12
-
13
Grade system.
منشور في 2025"…Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81–1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84–1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92–1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58–1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18–1.95) between BCG and placebo groups. …"
-
14
Literature search.
منشور في 2025"…Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81–1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84–1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92–1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58–1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18–1.95) between BCG and placebo groups. …"
-
15
Study characteristics.
منشور في 2025"…Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81–1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84–1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92–1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58–1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18–1.95) between BCG and placebo groups. …"
-
16
Flowchart of literature retrieval.
منشور في 2025"…Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81–1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84–1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92–1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58–1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18–1.95) between BCG and placebo groups. …"
-
17
Data extraction.
منشور في 2025"…Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81–1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84–1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92–1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58–1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18–1.95) between BCG and placebo groups. …"
-
18
Cochrane Collaboration’s risk of bias tool.
منشور في 2025"…Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81–1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84–1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92–1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58–1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18–1.95) between BCG and placebo groups. …"
-
19
Meta Analysis for Effectiveness of RFX for Primary and Secondary Prevention.
منشور في 2025الموضوعات: -
20
Subgroup Meta Analysis for HE Incidence Based on Treatment Duration and Dose.
منشور في 2025الموضوعات: